Exercise and Cardiac Stunning During HD
Launched by UNIVERSITY OF MANITOBA · May 3, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a 12-week cycling program during hemodialysis (a treatment for end-stage kidney disease) affects heart function in adults. Specifically, it aims to see if this exercise can help reduce a condition called "myocardial stunning," which is when the heart doesn't work as well after being stressed during dialysis. The study is currently looking for participants who are 18 years or older, have been on hemodialysis for at least three months, and can safely exercise as determined by their doctor.
If you or a loved one decides to participate, you will engage in cycling exercises while receiving dialysis three times a week for 12 weeks. It's important to note that those with certain recent heart conditions or severe breathing problems won't be eligible to join. This trial is a great opportunity for those looking to potentially improve their heart health while undergoing treatment for kidney disease, and all participants will be closely monitored for their safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults greater than or equal to 18 years old (no upper age limit); who are greater than; 3 months after starting maintenance hemodialysis
- • No expected change in dialysis modality, elective surgery or relocation outside of study site during the intervention period (16 weeks)
- • Assessed to be safe and able to exercise by the hemodialysis unit nephrologist
- • Able to communicate in English and provide written informed consent
- • Must be dialyzing thrice weekly
- Exclusion Criteria:
- • Acute coronary syndrome in the past 3 months
- • Unstable arrhythmia
- • Shortness of breath at rest or with minimal activity (NYHA Class 4)
- • Symptomatic hypoglycemia (\>2x/week in week prior to enrolment)
- • Participating in clinical intradialytic cycling program in last 3 months (if a clinical program exists)
About University Of Manitoba
The University of Manitoba, a leading research institution in Canada, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive expertise in medical research, public health, and community engagement to conduct rigorous and ethical clinical studies. The institution aims to translate scientific findings into practical applications that enhance patient care and improve health outcomes. Committed to fostering a culture of excellence and integrity, the University of Manitoba prioritizes participant safety and scientific validity in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winnipeg, Manitoba, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Winnipeg, Manitoba, Canada
Adelaide, South Australia, Australia
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Clara Bohm, MD, MPH
Principal Investigator
University of Manitoba
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials